Drug · Small Molecule
Sodium Iodide 131 I
CI-DRUG-00000710Explore in graph →CHEMBL1201084 Approved
Regulatory
Approvals (8)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| CA Health Canada | — | Marketed in Canada as SODIUM IODIDE (131I) SOLUTION (DIN 02439905) under ATC V10XA01 SODIUM IODIDE 131 I. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | Mar 4, 2016 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as HICON (DIN 02482339) under ATC V10XA01 SODIUM IODIDE 131 I. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawnsource: Dormantsince Jul 19, 2019 | Sep 29, 2009 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as HICON (DIN 02327864) under ATC V10XA01 SODIUM IODIDE 131 I. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawnsource: Dormant |
Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.
Data updated 15 days agoSource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Approved | Phase 2 | 0 | 0 | 0 | 1 | 8 | CA | Jun 30, 2009 | Sep 15, 2021 |
| Malignant Thyroid Gland Neoplasm | Phase2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 15, 2021 |
- Source
- clinicaltrials
- Layer
- derived (computed by CancerIndex)
Curated evidence
Clinical evidence (0)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
Data not yet available
Clinical trials
Trials with this intervention (1)
Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04952493 | Anlotinib or Penpulimab in Combination With RAI for DTC | unknown | Phase 2 | 42 | Peking Union Medical College HospitalOTHER | 1 | Jan 28, 2022 | clinicaltrials |